Last reviewed · How we verify
concurrent capecitabine or 5-FU
At a glance
| Generic name | concurrent capecitabine or 5-FU |
|---|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer (PHASE3)
- Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer (PHASE2)
- SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer (PHASE1)
- Adaptive Radiation in Anal Cancer (NA)
- Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer (PHASE3)
- Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer (PHASE3)
- Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer (PHASE3)
- Window of Opportunity Study in Colorectal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: